Grail, the liquid biopsy startup, picks an approach for its cancer test

Grail, the liquid biopsy startup, picks an approach for its cancer test

Play Episode Pause Episode

Mute/Unmute Episode Rewind 10 Seconds 1x Fast Forward 30 seconds

00:00 /

RSS Feed

Share

Link

Embed

Grail, the company that has raised $1.6 billion to develop a blood test to detect cancer early, announced that it has settled on a method for its test.